Catalent wins vaccine grant; TD2 partners up for cancer trials;

> CRO TD2 has partnered with Navigating Cancer, a patient-engagement outfit, to collaborate on clinical trials. Item

> Catalent ($CTLT) received a grant to help develop vaccines that don't need cold-chain storage. More

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.